In connective tissue diseases, autoantibodies cause pulmonary interstitial inflammation and fibrosis, and patients require treatment with an immunosuppressive agent such as a steroid. Dermatomyositis is an incurable, uncommon form of connective tissue disease that occasionally causes diffuse pulmonary inflammation leading to acute severe respiratory failure. In such cases, the prognosis is very poor despite treatment with high-dose steroid. In the present case, a 46-year-old man was admitted to our hospital with dyspnea. He was diagnosed with dermatomyositis combined with cryptogenic organizing pneumonia (COP) with respiratory failure and underwent treatment with steroid and an immunosuppressive agent, but the COP was not improved. However, the respiratory failure did improve after treatment with intravenous immunoglobulin, which therefore can be considered a treatment option in cases where steroids and immunosuppressive agents are ineffective.
bilateral ground-glass opacity (Fig. 2) . Magnetic resonance imaging of the thigh suggested atypical myositis (Fig. 3) . In an electromyography test, vastus lateralis and rectus femoris had decreased insertional activity, and motor unit potentials had lower amplitudes and early recruitment patterns. The Hreflex was normal, compatible with myopathy.
On the basis of these findings, ILD and acute respira- Immunosuppressive agents including steroids are used to treat ILD combined with dermatomyositis. Prednisone 1 mg/kg is used for initial and maintenance treatment and is tapered in accordance with the symptoms of patients. [12, 13] [5] In a third report, a 64-year-old patient who suffered an adverse effect from steroid and secondary immunosuppressive agents was treated successfully with i.v. immunoglobulin, [16] and in a further report, immunoglobulin treatment in progressive ILD resulted in positive progress. [17] At present, the treatment for ILD combined with dermatomyositis is mainly steroid and secondary immunosuppressive agents. There is no clear recommendation for use of intravenous immunoglobulin and no convincing mechanism of action has been presented. Nonetheless, some studies have reported that immunoglobulin is effective in treatment of dermatomyositis and ILD. In the present case, i.v. immunoglobulin was used successfully to treat ILD unresponsive to steroid and immunosuppressive agents.
